A global pharmaceutical company was preparing to file a reimbursement dossier for the prevention of migraine in Canada and Europe.

Our client had recently received EMA approval for a novel androgen receptor inhibitor, indicated within several solid tumors.

Our client had a Phase III biosimilar for the treatment of febrile neutropenia in the pipeline, with an estimated 5-years to launch

Our client had a late-stage vaccine candidate targeting older adult (OA) respiratory syncytial virus (RSV), and wanted support with its US pricing and access strategy.

A global pharmaceutical company had a Phase II/III enzyme replacement therapy in development for a rare genetic disorder that targeted symptoms not addressed by current standard of care.

Windrose conducted a pricing, market access and evidence gap assessment across US, EU4 and UK for two novel agents in a muscle weakness disorder

Our client was evaluating an orphan indication for Product X, which is currently indicated for another orphan indication in Europe, Japan, and Latin America.

Our client has a successful JAK inhibitor, “Product X”, which has large volumes of sales in the US; Product X sales are expected to continue to grow in the EU5, particularly through indication expansion.

Our client had a novel oral anticoagulant (NOAC) indicated for thromboembolic disorders on the market, which had seen significant commercial success and sales growth since its launch.

Our client had to make a business development decision regarding a potential new asset which would be developed in ulcerative colitis (UC) and atopic dermatitis (AtD).

Our client wanted to understand the non-muscle invasive bladder cancer (NMIBC) disease landscape, specifically for high-risk patients unresponsive to current non-surgical standard of care, for Germany, France, and Canada.

A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines

Product X is seeking approval in locally advanced or metastatic urothelial carcinoma (i.e. bladder cancer) as a monotherapy and as a 2nd Line (2L) option

Product X is expected to gain accelerated approval based on an open label, single-arm Phase II study

Objective: Develop a clear understanding of US payer perceptions of key value drivers and potential price ranges, and to form the basis for preliminary payer value story and proposition

A global pharmaceutical company was developing a new product for the treatment of Parkinson’s disease; the product had a novel mechanism of action and was in early phase of clinical development

A global pharmaceutical company’s R&D portfolio included several combination products across multiple different disease states.

A biopharmaceutical company was developing the first gene therapy for a rare disease. It was expected to be a one-time therapy that would replace the current chronic standard of care.

A global pharmaceutical company was planning to launch a next generation vaccine into a competitive market with the aim of replacing the current standard of care, which was a vaccine that they also owned.

A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines.